Bacterial infections caused by 'superbugs' are increasing globally, and conventional
antibiotics are becoming less effective against these bacteria, such that we risk entering a …

The need for new antibacterial drugs to treat the increasing global prevalence of drug-
resistant bacterial infections has clearly attracted global attention, with a range of existing …

Antimicrobial peptides (AMPs) or host defense peptides protect the host against various
pathogens such as yeast, fungi, viruses and bacteria. AMPs also display immunomodulatory …

The first antibiotic, salvarsan, was deployed in 1910. In just over 100 years antibiotics have
drastically changed modern medicine and extended the average human lifespan by 23 …

Pseudomonas aeruginosa is an important Gram-negative opportunistic pathogen which
causes many severe acute and chronic infections with high morbidity, and mortality rates as …

We are experiencing an antimicrobial resistance (AMR) crisis, brought on by the drying up of
the antibiotic discovery pipeline and the resulting unchecked spread of resistant pathogens …

Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity
and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of …

Discovery of antibiotics acting against Gram-negative species is uniquely challenging due to
their restrictive penetration barrier. BamA, which inserts proteins into the outer membrane, is …

Cyclic peptides are fascinating molecules abundantly found in nature and exploited as
molecular format for drug development as well as other applications, ranging from research …

Lipopolysaccharide (LPS) is a crucial constituent of the outer membrane of most Gram-
negative bacteria, playing a fundamental role in the protection of bacteria from …